Conventional influenza vaccines influence the performance of a universal influenza vaccine in mice.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Vaccine

• Publication date

  2017-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2017.11.065PMID 29249542
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevention and Control of Seasonal Influenza with Vaccines.

  2016cited by this paper
• Recapitulating adult human immune traits in laboratory mice by normalizing environment

  2016cited by this paper
• Universal influenza vaccines: Shifting to better vaccines

  2016cited by this paper
• Development of Cross-Protective Influenza A Vaccines Based on Cellular Responses

  2015cited by this paper
• Deaths averted by influenza vaccination in the U.S. during the seasons 2005/06 through 2013/14☆

  2015cited by this paper
• Cytomegalovirus (CMV) seropositivity decreases B cell responses to the influenza vaccine.

  2015cited by this paper
• Intranasal Adenovirus-Vectored Vaccine for Induction of Long-Lasting Humoral Immunity-Mediated Broad Protection against Influenza in Mice

  2014cited by this paper
• Mucosal Immunization with a Candidate Universal Influenza Vaccine Reduces Virus Transmission in a Mouse Model

  2014cited by this paper
• Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.

  2014cited by this paper
• T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine.

  2014cited by this paper
• Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults

  2013cited by this paper
• Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005–2011

  2013cited by this paper
• Cutting Edge: Rapid Boosting of Cross-Reactive Memory CD8 T Cells Broadens the Protective Capacity of the Flumist Vaccine

  2013cited by this paper
• Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice

  2012cited by this paper
• Cold-Adapted Influenza and Recombinant Adenovirus Vaccines Induce Cross-Protective Immunity against pH1N1 Challenge in Mice

  2011cited by this paper
• TLR3-Specific Double-Stranded RNA Oligonucleotide Adjuvants Induce Dendritic Cell Cross-Presentation, CTL Responses, and Antiviral Protection

  2011cited by this paper
• Advances in the assessment and control of the effector functions of therapeutic antibodies

  2011cited by this paper
• Seasonal FluMist Vaccination Induces Cross-Reactive T Cell Immunity against H1N1 (2009) Influenza and Secondary Bacterial Infections

  2011cited by this paper
• Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses

  2010cited by this paper
• Cross-protective immunity to influenza A viruses

  2010cited by this paper
• Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.

  2009cited by this paper
• Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies.

  2008cited by this paper
• A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus1

  2008cited by this paper
• Fc-receptors as regulators of immunity.

  2007cited by this paper
• Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1

  2007cited by this paper
• Priming with Cold-Adapted Influenza A Does Not Prevent Infection but Elicits Long-Lived Protection against Supralethal Challenge with Heterosubtypic Virus1

  2007cited by this paper
• Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

  2005cited by this paper
• Homotypic and heterotypic immunity of influenza A viruses induced by recombinants of the cold-adapted master strain A/Ann Arbor/6/60-ca

  2005cited by this paper
• Complement Component C1q Enhances the Biological Activity of Influenza Virus Hemagglutinin-Specific Antibodies Depending on Their Fine Antigen Specificity and Heavy-Chain Isotype

  2002cited by this paper
• Heterosubtypic Immunity to Influenza A Virus in Mice Lacking IgA, All Ig, NKT Cells, or γδ T Cells1

  2001cited by this paper
• Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells.

  2001cited by this paper
• Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection.

  1999cited by this paper
• Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein.

  1999cited by this paper
• Interleukin-4 causes delayed virus clearance in influenza virus-infected mice

  1996cited by this paper
• Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection

  1994cited by this paper
• Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity.

  1994cited by this paper
• The influenza virus variant A/FM/1/47-MA possesses single amino acid replacements in the hemagglutinin, controlling virulence, and in the matrix protein, controlling virulence as well as growth

  1994cited by this paper
• A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains

  1993cited by this paper
• Lymphokine control of in vivo immunoglobulin isotype selection.

  1990cited by this paper
• Purified influenza virus nucleoprotein protects mice from lethal infection.

  1987cited by this paper

• Dissecting immunological mechanisms underlying influenza viral nucleoprotein-induced mucosal immunity against diverse viral strains

  2024cites this paper
• Hemagglutinin Nanoparticulate Vaccine with Controlled Photochemical Immunomodulation for Pathogenic Influenza‐Specific Immunity

  2021cites this paper
• The effect of respiratory viruses on immunogenicity and protection induced by a candidate universal influenza vaccine in mice

  2019cites this paper
• Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus

  2018cites this paper
• The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine

  2018cites this paper
• Modulation of transdermal drug delivery with coated microneedles

  2018cites this paper
• Combined use of live-attenuated and inactivated influenza vaccines to enhance heterosubtypic protection.

  2018cites this paper
• Detection Methods of Human and Animal Influenza Virus—Current Trends

  2018cites this paper